Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases: Health-related Quality of Life Outcomes. (November 2021)
- Record Type:
- Journal Article
- Title:
- Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases: Health-related Quality of Life Outcomes. (November 2021)
- Main Title:
- Phase I/II Dose-Escalation Trial of 3-Fraction Stereotactic Radiosurgery for Resection Cavities From Large Brain Metastases
- Authors:
- Rahimy, Elham
Dudley, Sara A.
von Eyben, Rie
Pollom, Erqi L.
Seiger, Kira
Modlin, Leslie
Wynne, Jacob
Fujimoto, Dylann
Jacobs, Lisa R.
Chang, Steven D.
Gibbs, Iris C.
Hancock, Steven L.
Adler, John R.
Li, Gordon
Choi, Clara Y.H.
Soltys, Scott G. - Abstract:
- Abstract : Objectives: We investigated differences in quality of life (QoL) in patients enrolled on a phase I/II dose-escalation study of 3-fraction resection cavity stereotactic radiosurgery (SRS) for large brain metastases. Methods: Eligible patients had 1 to 4 brain metastases, one of which was a resection cavity 4.2 to 33.5 cm 3 . European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaires core-30 (QLQ-30) and brain cancer specific module (QLQ-BN20) were obtained before SRS and at each follow-up. Nine scales were analyzed (global health status; physical, social, and emotional functioning; motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty). QoL was assessed with mixed effects models. Differences ≥10 points with q -value (adjusted P -value to account for multiplicity of testing) <0.10 were considered significant. Results: Between 2009 and 2014, 50 enrolled patients completed 277 QoL questionnaires. Median questionnaire follow-up was 11.8 months. After SRS, insomnia demonstrated significant improvement ( q =0.032, −17.7 points at 15 mo post-SRS), and future uncertainty demonstrated significant worsening ( q =0.018, +9.9 points at 15 mo post-SRS). Following intracranial progression and salvage SRS, there were no significant QoL changes. The impact of salvage whole brain radiotherapy could not be assessed because of limited data (n=4 patients). In the 28% of patients that had adverse radiation effect, QoLAbstract : Objectives: We investigated differences in quality of life (QoL) in patients enrolled on a phase I/II dose-escalation study of 3-fraction resection cavity stereotactic radiosurgery (SRS) for large brain metastases. Methods: Eligible patients had 1 to 4 brain metastases, one of which was a resection cavity 4.2 to 33.5 cm 3 . European Organization for Research and Treatment of Cancer (EORTC) quality of life questionnaires core-30 (QLQ-30) and brain cancer specific module (QLQ-BN20) were obtained before SRS and at each follow-up. Nine scales were analyzed (global health status; physical, social, and emotional functioning; motor dysfunction, communication deficit, fatigue, insomnia, and future uncertainty). QoL was assessed with mixed effects models. Differences ≥10 points with q -value (adjusted P -value to account for multiplicity of testing) <0.10 were considered significant. Results: Between 2009 and 2014, 50 enrolled patients completed 277 QoL questionnaires. Median questionnaire follow-up was 11.8 months. After SRS, insomnia demonstrated significant improvement ( q =0.032, −17.7 points at 15 mo post-SRS), and future uncertainty demonstrated significant worsening ( q =0.018, +9.9 points at 15 mo post-SRS). Following intracranial progression and salvage SRS, there were no significant QoL changes. The impact of salvage whole brain radiotherapy could not be assessed because of limited data (n=4 patients). In the 28% of patients that had adverse radiation effect, QoL had significant worsening in 3 metrics (physical functioning, q =0.024, emotional functioning q =0.001, and future uncertainty, q =0.004). Conclusions: For patients treated with 3-fraction SRS for large brain metastasis cavities, 8 of 9 QoL metrics were unchanged or improved after initial SRS. Intracranial tumor progression and salvage SRS did not impact QoL. Adverse radiation effect may be associated with at least short-term QoL impairments, but requires further investigation. Abstract : Supplemental Digital Content is available in the text. … (more)
- Is Part Of:
- American journal of clinical oncology. Volume 44:Number 11(2021)
- Journal:
- American journal of clinical oncology
- Issue:
- Volume 44:Number 11(2021)
- Issue Display:
- Volume 44, Issue 11 (2021)
- Year:
- 2021
- Volume:
- 44
- Issue:
- 11
- Issue Sort Value:
- 2021-0044-0011-0000
- Page Start:
- Page End:
- Publication Date:
- 2021-11
- Subjects:
- quality of life -- fractionated radiosurgery -- brain metastases -- resection -- prospective
Cancer -- Treatment -- Periodicals
Oncology -- Periodicals
Tumors -- Periodicals
616.994005 - Journal URLs:
- http://ovidsp.ovid.com/ovidweb.cgi?T=JS&NEWS=n&CSC=Y&PAGE=toc&D=yrovft&AN=00000421-000000000-00000 ↗
http://www.amjclinicaloncology.com ↗
http://journals.lww.com ↗ - DOI:
- 10.1097/COC.0000000000000868 ↗
- Languages:
- English
- ISSNs:
- 0277-3732
- Deposit Type:
- Legaldeposit
- View Content:
- Available online (eLD content is only available in our Reading Rooms) ↗
- Physical Locations:
- British Library DSC - 0823.500000
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store - Ingest File:
- 25080.xml